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stage I, II, IIIA, and IIIB, respectively. Median age was 61.7 
years (range: 35-87). After a median planned gap of 2 weeks 
(range, 0-4; no gap in 25 patients since 2011), a boost dose 
was delivered with either IMRT (n = 16, until 2011), VMAT (n 
= 16), HT (n = 37) or 3D-CRT (n = 68). Concomitant CTX was 
delivered in 127 patients, maily using a mitomycine-
capecitabine combination (n = 117). Median follow-up was 42 
months (range: 2-97). Four-year LC, OS, DFS, and CFS rates 
were 80%, 84%, 78% and 90%, respectively. Time to 
progression was 4 months (range: 0-41). A total of 24 patients 
presented a recurrence (local only in 14, locoregional in 1, 
locoregional and distant in 1, local and distant in 3, regional 
only in 2, and distant only in 3 patients). Twelve patients 
underwent a colostomy because of local recurrence (n = 12) 
or pretreatment dysfunction (n = 2). Grade 3 acute toxicity 
was observed in 33 patients (2.4%); i.e. erythema (26/33) or 
diarrhoea (9/33). No late G3 cutaneous toxicity was 
recorded. At the time of analysis, 127 patients presented 
more than 6 months of followup and were considered 
evaluable for late toxicity: 5 of 127 patients present a late 
G3 gastrointestinal toxicity (anal incontinence). No G4 acute 
or late toxicity was recorded. No significant difference was 
observed in terms of local control or acute G3 toxicity 
between MRT techniques and 3D-CRT boost techniques. 
Conclusions: A total dose of 59.4 Gy to the anal canal and 
involved nodes, including 36 Gy to the uninvolved nodes, is 
effective and safe when delivered using modern IMRT 
techniques and daily IGRT. For these reasons, VMAT or HT 
and concurrent CTX are the standard of care in our 
institutions. 
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Purpose/Objective: To evaluate the efficacy of proton beam 
therapy (PBT) for hepatocellular carcinoma with extensive 
tumor thrombosis in the main trunk or major branches of the 
portal vein. 
Materials and Methods: Eighty patients with hepatocellular 
carcinoma were treated by PBT. There were 65 men and 15 
women, and the median age was 65 years old (range: 25 – 
88). The CTV ranged from 15.2 cm3 to 1687 cm3 (median: 
238.9 cm3). The clinical stages were 3B, 3C, 4A, and 4B in 65, 
1, 5, and 9 patients, respectively. Thirty-two patients had 
primary tumors, and 48 had recurrent tumors. The delivered 
total dose ranged from 70 to 80.47 Gy10 (median: 80.47Gy10) 
in terms of equivalent dose in 2Gy fractions. 
Results: Seventy-seven patients (96.3%) completed the 
planned treatment. Median survival rate for all the patients 
was 12 months. MST for the patients treated with PTV that 
encompassed all the detectable lesions was 26.9 months, and 
MST for the patients who had viable tumor outside of their 
PTV was 6.3 months. Local recurrence after PBT was 
observed in 3 patients. Forty-five patients died of tumor 
progression, and 28 of them had recurrence out of the PTV. 
Multivariate analysis revealed existence of viable tumor 
outside of the PTV, clinical stage, and value of des-gamma-
carboxy prothrombin as significant factors affecting the OS. 
Conclusions: PBT was effective for patients with extensive 
portal tumor thrombus, if the PTV encompassed all the 
detectable lesions.  
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Purpose/Objective: Some studies already showed that acute 
toxicity during chemo +/- radiotherapy (CT +/- RT) was 
correlated to the clinical response of the tumor. In this 
retrospective study, we report our analysis of acute toxicity 
of rectal cancer cancer patients treated with an homogenous 
schedule of CT +/- RT. 
Materials and Methods: Between 01/2010 and 08/2014, 83 
locally advanced rectal cancer patients consecutively treated 
in our institution were analyzed. All these patients received 
long-course neoadjuvant chemoradiotherapy (45 Gy on pelvic 
nodes and mesorectum and 50 Gy on gross tumor volume and 
corresponding mesorectum, delivered with a simultaneous 
integrated boost). All patients were treated with helical 
Tomotherapy (HT) and daily image guided radiotherapy, and 
all of them underwent radical surgery. Concomitant 
chemotherapy with oral capecitabine was delivered in all the 
patients. Primary endpoint of this study was to report the 
rate of acute toxicity (G2 or more) of this therapeutic 
approach and to correlate acute toxicity to the Mandard 
tumor regression rate (TRG). Toxicity were retrospectively 
scored using CTC-AE score (v. 4.0). The considered acute 
toxicity were: skin toxicity, diarrhoea, blood loss, cystitis, 
anorectal pain. We performed logistic regression analyses, 
and we correlated the TRG with the presence of acute 
toxicity (any grade), the presence of any acute toxicity grade 
> 2, and with a 'sum of toxicity' (ST) of each toxicity grades 
(i.e: this ST in a patient presenting a G2 bladder toxicity , a 
G1 pain and a G3 diarrhoea was 6, 2+1+3). 
Results: Globally, 22/83 patients presented an acute > G2 
toxicity (26.5%), with only one patients presenting a G3 acute 
skin toxicity. Data about TRG were available for 69 patients. 
Logistic regression showed that better TRG have been found 
in patients presenting higher TS, both when TRG was 
considered as an ordinal (p=0.028) or as a continuous variable 
(p=0.03). 
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Conclusions: Long-course chemo-radiotherapy with 
simultaneous integrated boost is safe in the treatment of 
rectal cancer patients. Patients presenting more pronounced 
and/or several toxicity showed a significant trend toward a 
better TRG. Immunological local reactions could potentially 
explain these results, and should be further explored. 
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Purpose/Objective: UK IMRT anal cancer treatment uses 
large fields to uninvolved nodal groups (40Gy) with 
simultaneous integrated boost to the primary tumour (50.4Gy 
T1/T2; 53.2Gy T3/T4) and involved nodes (50.4Gy). With a 
simple bony match online, iliac nodes are well covered and 
the margins required are well documented, however the 
margins for prophylactic inguinal nodes (pIN) and primary 
tumour are not well established as data from daily imaging 
are limited; these form the focus of this study. 
Materials and Methods: Anal cancer patients treated at a 
single institution under current UK IMRT guidelines were 
screened; 11 consecutive inguinal node negative patients 
were studied. Supine treatment comprised 28 fractions with 
daily imaging: CBCT fractions 1-5, 10, 15, 20 and 25; 
orthogonal kV imaging all other fractions. 
99 CBCT’s were re-matched automatically to the planning 
CT. A bony match was performed using a clipbox 
encompassing the bony pelvis. Re-matches were performed 
within the same clipbox using the clinician defined tumour 
(GTVA) as a region of interest (ROI), then repeated with the 
pIN ROI. Accuracy of auto-matches were assessed visually to 
ensure clinical relevance. 
Bony match values were subtracted from the GTVA and pIN 
measurements to evaluate differences in the optimal 
treatment position for the tumour or the nodes relative to a 
simple bony match. Margins were calculated using van Herk’s 
recipe.  
Results: Differences (mm) between GTVA/ bony matches 
were larger than inguinal/ bony matches in all axes ( lat -3.1 
to 4.2; -2 to 1.5, vert- 6.9 to 12.7; -3.6 to 2.9, long -13.3 to 
17.2; -8.5 to 7.3 in GTV and pIN respectively). This was 
statistically significant in the long axis (p<0.05) shown in 
Fig.1. GTVA had consistently larger systematic and random 
errors than pIN, reflected in the margin calculations (mm): 
GTVA lat 2.8, long 9.8, vert 5.8; pIN lat 1.5, long 3.1, vert 
3.1. 
Conclusions: With a simple bony match, the margin around 
pIN can be reduced to 1.5mm laterally and 3.1mm in all 
other directions potentially reducing toxicity to the groin, 
genitalia and bladder. 
The GTVA to PTV margin incorporates microscopic disease, 
the motion of the soft tissues of the anus which can be 
affected by tumour size, location, bowel filling and BMI; and 
the set up error. The margin reported in this study covers set 
up error and soft tissue motion of the anus. An individualised 
margin incorporating these factors can be calculated and 
applied during the treatment course with the aim of reducing 
toxicity in adjacent organs such as vagina, bladder and penile 
bulb.  
Further investigation is warranted to demonstrate reduced 
toxicities with these strategies. 
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Purpose/Objective: Multidisciplinary clinics (MDCs) offer 
patients an initial evaluation by all three oncologic 
specialists, radiologists, pathologists, and others. The costs 
and overall value (defined as quality divided by costs) of care 
in MDCs are not well-described. For patients with pancreatic 
cancer, we compared direct care costs, patient retention 
rates, patient phone calls with symptoms, patient ED visits 
with symptoms, and survival outcomes for patients treated in 
a pancreatic MDC to patients evaluated outside of the MDC. 
Materials and Methods: Two cohorts of patients with 
pancreatic cancer seen at our institution were analyzed and 
